| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenues [Abstract] | |||||||||||
Revenues | |||||||||||
7,863 | 6,710 | 5,872 | 4,860 | 4,103 | 2,819 | 2,104 | 1,378 | 445 | 459 | 379 | 238 |
Sanofi collaboration revenue | |||||||||||
- | - | - | - | 758 | 541 | 430 | 423 | 326 | 311 | 247 | 153 |
Bayer Collaboration Revenue | |||||||||||
- | - | - | - | 580 | 495 | 220 | 70 | 43 | 75 | 67 | 31 |
Other revenue | |||||||||||
- | - | - | - | 74 | 31 | 28 | 26 | 31 | 40 | 40 | 40 |
Other revenue | |||||||||||
- | - | - | - | - | - | - | - | - | 6 | 6 | 7 |
Expenses: | |||||||||||
Research and development | |||||||||||
3,036 | 2,186 | 2,075 | 2,052 | 1,620 | 1,271 | 859 | 625 | 529 | 489 | 398 | 274 |
Selling, general, and administrative | |||||||||||
1,834 | 1,556 | 1,320 | 1,177 | 838 | 519 | 346 | 210 | 117 | 65 | 52 | 48 |
Total expenses | |||||||||||
5,653 | 4,176 | 3,792 | 3,529 | 2,851 | 1,995 | 1,361 | 920 | 650 | 556 | 453 | 324 |
Income from operations | |||||||||||
2,209 | 2,534 | 2,079 | 1,330 | 1,251 | 823 | 743 | 457 | -205 | -97 | -74 | -86 |
Other income (expense): | |||||||||||
Other (expense) income, net | |||||||||||
249 | 47 | 24 | 6 | -12 | -25 | -0 | - | - | - | - | - |
Investment income | |||||||||||
- | - | - | - | - | - | - | 2 | 3 | 2 | 4 | 18 |
Interest expense | |||||||||||
30 | 28 | 25 | 7 | -14 | -37 | 46 | 45 | 21 | 9 | 2 | 7 |
Loss on Extinguishment of Debt | |||||||||||
- | - | - | - | - | - | 0 | 0 | - | - | - | -0 |
Total other income (expense) | |||||||||||
219 | 19 | -1 | -0 | -26 | -62 | -46 | -43 | -17 | -6 | 2 | 9 |
Income before income taxes | |||||||||||
2,429 | 2,553 | 2,078 | 1,329 | 1,225 | 761 | 696 | 414 | -222 | -104 | -71 | -76 |
Income tax expense | |||||||||||
313 | 109 | 880 | 434 | 589 | 423 | 282 | -335 | -1 | 0 | -4 | 2 |
Net Income (Loss) Attributable to Parent | |||||||||||
2,115 | 2,444 | 1,198 | 895 | 636 | 338 | 413 | 750 | -221 | -104 | -67 | -79 |
Net income per share - basic (in dollars per share) | |||||||||||
19.38 | 22.65 | 11.27 | 8.55 | 6.17 | 3.36 | 4.23 | 7.92 | -2.45 | -1.26 | - | - |
Net income per share - diluted (in dollars per share) | |||||||||||
18.46 | 21.29 | 10.34 | 7.70 | 5.52 | 2.98 | 3.72 | 6.75 | -2.45 | -1.26 | - | - |
Weighted average shares outstanding - basic (in shares) | |||||||||||
109 | 107 | 106 | 104 | 103 | 100 | 97 | 94 | 90 | 82 | - | - |
Weighted Average Number of Shares Outstanding, Diluted | |||||||||||
114 | 114 | 115 | 116 | 115 | 113 | 111 | 115 | 90 | 82 | - | - |
Other comprehensive income (loss), net of tax: | |||||||||||
Unrealized (loss) gain on debt securities | |||||||||||
35 | -7 | 12 | -21 | -43 | 53 | -0 | 0 | 0 | -3 | - | - |
Unrealized loss on cash flow hedges | |||||||||||
-2 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - |
Comprehensive income | |||||||||||
2,149 | 2,438 | 1,212 | 874 | 592 | 391 | 413 | 750 | -221 | -108 | - | - |
Net loss per share, basic and diluted (in dollars per share) | |||||||||||
- | - | - | - | - | - | - | - | - | - | -0.85 | -1.00 |
Weighted average shares outstanding, basic and diluted (in shares) | |||||||||||
- | - | - | - | - | - | - | - | - | - | 79 | 78 |
Product | |||||||||||
Revenues | |||||||||||
4,834 | 4,106 | 3,718 | 3,338 | 2,689 | 1,750 | 1,425 | 858 | 44 | 25 | 18 | 6 |
Cost of goods sold | |||||||||||
362 | 180 | 202 | 194 | 241 | 129 | 118 | 83 | 4 | 2 | 1 | 0 |
Collaboration and contract manufacturing | |||||||||||
Cost of goods sold | |||||||||||
419 | 254 | 194 | 105 | 151 | 75 | 37 | 0 | 0 | - | - | - |